Summary Preliminary data would suggest that the pineal hormone, melatonin (MLT), may enhance tamoxifen (TMX) 
According to preliminary experimental observations, many solid neoplasms would seem to be characterised by a partial hormone dependency, including cancer of pancreas, hepatocarcinoma, renal cell carcinoma, gynaecological tumours and melanoma, even though endocrine receptor expression has still to be clinically investigated in these neoplasms. However, classical endocrine therapy with anti-oestrogen and antiandrogen agents is ineffective in inducing objective tumour regressions in solid neoplasms, other than breast and prostate cancer. Moreover, standard anti-cancer hormonotherapies consist of an administration of anti-hormones, whereas there are only very preliminary data concerning the possibility of treating human neoplasms with endogenous oncostatic hormones. At present, the most investigated endogenous anti-tumour hormone is the pineal hormone, melatonin (MLT) (Regelson and Pierpaoli, 1987) , whose immunomodulating and oncostatic properties have been well demonstrated in experimental conditions. MLT has also improved the clinical status of untreatable metastatic solid tumour patients (Lissoni et al., 1991) , mainly by counteracting macrophage-mediated immunosuppression, or cachexia (Broder et al., 1978) , through inhibition of the release of tumour necrosis factor alpha (TNF-cx) (Beutler and Cerami, 1987) . Therefore, both the oncostatic and palliative effects of MLT and other endogenous immunomodulating substances have to be considered. In fact, whereas the well-being induced by palliative drugs, such as steroids, is generally compromised by undesirable biological effects, particularly the suppression of host anti-cancer defences, the improvement in the quality of life of advanced cancer patients achieved by MLT is associated with an enhanced immune performance (Lissoni et al., 1989) , as well as with a potential inhibitory effect on cancer cell proliferation, even though the evidence of objective tumour regressions is an extremely rare phenomenon during therapy with MLT alone. Tamoxifen (TMX) has been proven to have oncostatic effects in addition to its antioestrogen action, such as the inhibition of tumour growth factor secretion (Pollak et al., 1990 ) and the capacity for stimulating the secretion of transforming growth factor ,B (TGF-JJ) (Knabbe and Lippman, 1987) , which has been shown to inhibit the proliferation of several cancer cell lines. Unfortunately, TGF-,B is one of the most effective endogenous immunosuppressive agents, and, in particular, it appears to counteract the anti-neoplastic action of interleukin 2 (IL-2), whose importance in generating anti-tumour cytotoxic lymphocytes is well known (Inge et al., 1992 (UICC, 1978; WHO, 1976) . The duration of response and the overall survival time were calculated from the onset of therapy. Routine laboratory tests were repeated at weekly intervals for the first 3 months, then at 14 day intervals. Data were statistically analysed by the chi-square test, the Student's ttest and analysis of variance, as appropriate.
Results
The characteristics of patients and their clinical response are shown in Table I . No complete response was seen. Partial response (PR) was achieved in three cases (12%; 95% confidence limits 2-24%; duration, 5, 6 and 8 months). The first patient had multiple skin metastases caused by melanoma, mainly at the abdominal wall; the second patient showed abdominal node metastases as a result of uterine cervix carcinoma, with a median diameter of 2 cm, as assessed by MR; the third patient had multiple dorsal and lumbar vertebral bone metastases due to unknown primary tumour, and his response was assessed by radiographs, CT scan and MR. Thirteen other patients (52%) had stable disease (SD), with a median duration of 6 months (range 3-23 months), whereas the remaining nine (36%) patients had progressive disease (PD). All patients were followed up for at least 1 year. Survival for longer than 1 year was observed in 7/25 (28%) patients, and the percentage of 1 year survival, as evaluated according to the chi-square test, was significantly higher in patients with PR or SD than in those with PD (7/16 vs 0/9, P<0.05). No toxicity was found, and in particular no MLT-related toxicity was seen. On the contrary, most patients experienced a relief of depressant symptoms, anxiety and asthenia. Moreover, a clear improvement in PS occurred in 9/25 (36%) patients, whose median score increased from 50% (range 40-80%) before therapy to 70% (range 60-100%) on treatment.
Platelet numbers became within the normal range in 3/4 patients with cancer-related persistent thrombocytopenia, and platelet mean number seen on treatment, as expressed as maximum values on study, was significantly higher with respect to the pretreatment values (136 + 14 vs 72 + 8, nx I03 mm-3, mean+s.e., P<0.01). The first patient had multiple bone metastases due to unknown primary tumour, while the other two patients had portal hypertension syndrome caused by hepatocarcinoma and liver metastases as a result of cancer of the pancreas respectively. Finally, (Lissoni et al., 1989 (Lissoni et al., , 1991 , this phase II study would suggest that the concomitant administration of TMX may amplify the oncostatic activity of MLT, perhaps through a stimulation of TGF-f, release, even though at present there are no data about the effect of MLT plus TMX on TGF-,B secretion. Alternatively, MLT might amplify TMX efficacy, as suggested by the evidence of disease stabilisation in patients previously progressing on TMX alone, perhaps by stimulating endocrine receptor expression on cancer cells (Regelson and Pierpaoli, 1987) . Therefore, the results of the study may encourage examination of the mechanism of action of the TMX-MLT combination and performance of a randomised comparison with best supportive care. Finally, the evidence that the neuroendocrine combination of TMX and MLT may improve the PS of advanced cancer patients of poor clinical conditions would justify successive studies by associating well-tolerated monochemotherapies, such as low-dose epirubicin, vinorelbine or mitoxantrone, in an attempt to evaluate the possibility of obtaining more interesting results without worsening the quality of life of patients.
